|
|
||||||||
1 Departments of Biochemistry, Microbiology, and Immunology, and 2 Department of Physiology, Montreal Heart Institute, University of Montreal, Montreal, Quebec H3C 3J7; and 3 Department of Cellular and Molecular Medicine, Kidney Research Centre, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
| |
ABSTRACT |
|---|
|
|
|---|
Bradykinin (BK), a
proinflammatory factor and vasodilator, causes functional change of the
small artery. However, it is not clear whether any of these changes
induced by BK are mediated by
N-acetyl-D-sphingosine (ceramide). Therefore, we
investigated whether BK affects the hydrolysis of sphingomyelin and
generation of ceramide in the intact rat small artery. Our results
suggest that BK induces sphingomyelin hydrolysis and increases ceramide production in a time- and dose-dependent manner. Relative to controls, BK causes a 50% decrease in sphingomyelin levels. Ceramide levels increase in response to BK with the highest level being obtained with
10
8 M BK as well as similar amounts of ceramide are
generated when exogenous sphingomyelinase (SMase) is added. We then
determined which of the two BK receptors (BK-B1 antagonist
Lys-Des-Arg9-Leu8-BK or the BK-B2
antagonist HOE-140) are implicated in the BK-induced generation of
ceramide. The BK-B2 antagonist did not alter the effect of
BK on ceramide generation, whereas the BK-B1 antagonist blocked the BK-induced production of ceramide. Although ceramide had no
effect on KCl-induced constrictions, ceramide dilated preconstricted (phenylephrine) small pressurized rat mesenteric arteries by ~40%. These results suggest that the activation of the BK-B1
receptor mediates the BK-induced activation of SMase and of the
production of ceramide. In conclusion, BK-mediated effects on vascular
tone may be due, at least in part, to the increased production of ceramide.
phenylephrine; receptor antagonists; sphingomyelin; vascular tone
| |
INTRODUCTION |
|---|
|
|
|---|
THE FIELD OF SPHINGOLIPID and N-acetyl-D-sphingosine (ceramide) signal transduction has recently advanced rapidly. Experimental results (18, 19) suggest that ceramide has important roles in many cell types. Sphingomyelin (SM) is composed of long chain saturated or monounsaturated fatty acid, a sphingosine base backbone, and a phosphocholine head group (3, 5, 37). Hydrolysis and synthesis of the sphingolipids that form the SM pool together form a dynamic balanced pathway called the "sphingomyelin pathway." SM turnover involves removal of the head group and amide-linked fatty acid by sphingomyelinases (SMases) and ceramidases, respectively. SMase action is the only known mechanism for SM hydrolysis in mammalian cells. Most, if not all, mammalian cells appear capable of signaling through the SM pathway (29). SM that is present either on the outer or on the inner layer of the plasma membrane can be used to generate ceramide that is involved in signal transduction pathways (11). Exogenous SMases are mainly of bacterial origin and have become important tools for investigating ceramide signal transduction, in particular because few antagonists for endogenous SMases are available. In general, exogenous SMase mimics the effect of ceramide-generating signals and is effective in hydrolyzing endogenous SM (6, 8, 41). It has access to the bulk of cellular SM, which is located on the external portion of the lipid bilayer (36).
Ceramide has been proposed as a novel second messenger that mediates a variety of biological processes (18, 19). Specific stimuli induce SMase activity, which results in SM hydrolysis and ceramide production. Ceramide may activate or inhibit a variety of signals, for example: protein kinases, phosphatases, or phospholipases, which affect multiple downstream targets, including activation of nuclear transcription factors, leading to a variety of distinct cellular effects (19). A large variety of stimuli induce SM hydrolysis and ceramide formation (18, 19). There is evidence for extensive tissue specificity as indicated by the fact that for any given SMase activating stimulus, not all cells or tissues respond to that agent by hydrolyzing sphingomyelin; furthermore, different final effects can be obtained in different cell types in response to the same SMase activating agent (1, 12, 13).
As a novel lipid second messenger, ceramide derived from sphingolipids plays a central role in signal transduction and cell regulation. We (18) have previously shown that the effects of BK, a proinflammatory factor and vasodilator, were mediated by ceramide and by phospholipase D in cultured rabbit cortical collecting duct (RCCD) cells. In RCCD cells, BK increased SM levels and decreased ceramide levels. The BK-B1 receptor antagonist did not affect ceramide but the BK-B2 antagonist blocked the effect of BK on SMase, suggesting that the BK-B2 receptor mediates BK-induced inhibition of ceramide generation in RCCD cells. There is evidence in smooth muscle cells that sphingolipids are involved in regulating cell proliferation. For instance, in mesangial cells and A7R5 smooth muscle cells, platelet-derived growth factor increases sphingosine levels (19) by stimulating SMase and ceramidase activities (7). We do not have much information with regard to contractile responses. Cell-permeable ceramides and SMase treatment caused relaxation of phenylephrine (PE)-contracted endothelium-denuded rat thoracic aortic rings (16). In contrast, cell-permeable ceramide induced contraction of isolated rabbit rectosigmoid smooth muscle cells (35). However, in vascular smooth muscle, one effect of ceramide that may have particular relevance for smooth muscle contraction is the activation of the serine-threonine kinase Raf (15, 42), an upstream regulator of extracellular signal-regulated kinase (ERK) (34). Sphingosine induced vasoconstriction in coronary arteries, an effect that appeared to be mediated by the release of cyclooxygenase-sensitive vasoconstrictor prostanoids from the endothelium (24). Thus the SM pathway may be an important regulator of vascular function.
However, most studies to date have examined the role of ceramide in the context of cytokine signaling from cells in culture, whereas few studies have been done using intact tissues. No studies have been performed exploring the potential role of BK with regard to ceramide and SMase signaling by using intact tissues. Of interest, it is not known whether the effects of BK involve ceramide and SMase signaling nor whether the BK-induced increase in ceramide production may influence vascular tone in the intact pressurized rat mesenteric small artery. Therefore, we studied the effect of BK on ceramide and SMase in rat small artery.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Lipid Measurements
BK, Staphylococcus aureus, SMase, and all other standards, drugs, and salts were purchased from Sigma (St. Louis, MO). Medium 199 (M-199) was obtained from GIBCO-BRL. [Methyl-14C]choline chloride (specific activity 55.0 mCi/mmol) was supplied by Amersham. [14C]myristic acid (specific activity 40-60 mCi/mmol) was obtained from DuPont-New England Nuclear. Thin-layer chromatography (TLC) plates (0.25 mm thick) were purchased from Whatman. All solvents, acids used for lipid extraction such as chloroform and methanol, and high-perfomance liquid chromatography grade solvents were supplied by BDH.Animals and Tissue Preparation
Adult male Sprague-Dawley rats, body wt ~225-275 g, were anesthetized using Pentothal Sodium (Somnotol, MTC Pharmaceuticals). The mesentery was immediately excised and kept in ice-cold physiological salt solution composed of (in mM) 119 NaCl, 4.7 KCl, 25 NaHCO3, 1.17 MgSO4 · 7 H2O, 1.18 KH2PO4, 0.026 K2 EDTA, 5.5 glucose, and 2.5 CaCl2 · 2H2O, pH 7.2, until dissection. Adjoining fat and connective tissues were removed from the vessels with the use of a dissection microscope. Rat mesenteric arteries of ~280-300 µm internal diameter were used for all of the experiments. A collection of five small arteries, each of which was ~2 cm long, was used for each point; each sample contains ~40 µg of protein.Radiolabeling of small arteries. An appropriate aliquot of radioactive material was dried down under a stream of nitrogen, placed in 200 ml of M-199 solution and redissolved by bath sonication for 5 min. Vessels were incubated in M-199 solution for 3 h at 37°C, washed in 3 ml of M-199 for 15 min, and then transferred to 3 ml of fresh M-199 solution.
Solvent extraction of small artery lipids.
The lipid extraction method was based on that of Bligh and Dyer
(4) as described by Liu et al. (18). After BK
or SMase stimulation, the reaction was terminated by transferring the
vessels to an ice-cold ground glass homogenizer containing 0.5 ml
chloroform-methanol-HCl (20:40:1, vol/vol/vol), homogenized, and left
on ice for 30 min. The mixture was transferred to a microcentrifuge
tube and the homogenizer was rinsed with 1 ml of chloroform. These
washings were added to the tube along with 0.3 ml 1 M NaCl, vortexed,
and spun at 11,000 g for 5 min at 4°C. The upper aqueous
layer was discarded, and the lower layer, containing the lipids, was
transferred to a 1-ml glass Chrompack vial, dried under a stream of
N2, and redissolved in 200 µl of chloroform. Samples were
stored at
20°C until analyzed. The particulate protein interface
was air dried, dissolved in 0.5 ml 2 M NaOH, and assayed for protein
according to the method of Lowry et al. (20).
Measurement of sphingomyelin hydrolysis.
Because choline is a component of sphingolipids (10),
small arteries were prelabeled with 1 µCi/ml
[methyl-14C]choline chloride in M-199 solution
for 3 h at 37°C to label the sphingomyelin pool. Small arteries
were then stimulated with or without BK (10
8,
10
7, and 10
6 M) for 30 min. Lipids were
extracted and internal standards were added to each sample: 20 µl (10 mg/ml in chloroform) of SM + phosphatidylcholine. The TLC plates
were preheated to 80°C for 30 min. The samples (25 µl in
chloroform) were spotted onto the plates along with external standards:
SM + PC (20 µl of 10 mg/ml in chloroform). The plates were
developed in chloroform-methanol-acetic acid-water (50:30:8:5, vol/vol/vol/vol), dried, and stained with I2 to
mark the areas corresponding to SM and phosphorylcholine.
Measurement of [14C]ceramide production.
To investigate the time and concentration-response of ceramide
production to BK, [14C]myristic acid-labeled small
arteries were stimulated with BK for 1, 5, and 30 min with
10
10-10
6 M BK. Lipids were extracted
from small arteries and the 14C-labeled ceramide was
separated from other 14C-containing lipids by TLC using the
ethyl acetate-acetic acid-trimethylpentane solvent (9:2:5 vol/vol/vol).
To determine which BK receptor subtype mediates BK-induced ceramide
production, [14C]myristic acid-labeled small arteries
were stimulated with BK (10
8 M) for 30 min with or
without the BK-B1 receptor antagonist
(Lys-Des-Arg9-Leu8-BK, 1 µM) or the
BK-B2 receptor antagonist (HOE-140, 1 µM). Lipids were
then extracted from arteries, and the 14C-labeled ceramide
was separated from other 14C-containing lipids on TLC
plates. These experiments were repeated three times.
Measurement of radioactivity. [14C]SM and [14C]ceramide were measured using the Molecular Dynamics System with ImageQuaNT computer software. The developed TLC plates were exposed to phosphor screens for 72 h in exposure cassettes and were scanned with the phosphorimager. Results, obtained as volume per spot, are expressed as volume per milligram of protein. Volume calculations include the area and density of the radioactivity-generated spots. Results are expressed as a percentage of control.
Statistics
To determine the statistical significance of differences between more than two groups, analysis of variance and Bonferroni multiple comparison tests were used (18). Differences of P < 0.05 were considered statistically significant. Results are presented as means ± SE of 3-4 independent experiments.Functional Assays
Tissue preparation. Functional assays on intact pressurized rat mesenteric arteries were carried out as previously described (31) except that the endothelium was not removed. In brief, third-branch small arteries of ~7.5 mm in length (mean lumen diameter in the absence of transmural pressure was 158 ± 7 µm, n = 13) were carefully dissected from the vascular bed, mounted on borosilicate cannulas in a perfusion chamber, and attached using silk suture threads. Criteria for viability and suitability of the artery included constriction to boluses of 1 M KCl and 10 mM PE, respectively, followed by evidence for a significant endothelium-dependent dilation by exposing the preparation to a bolus of 1 mM acetylcholine, and no pressure leak between the proximal and distal ends of the vessel. Suitable arteries were then allowed to equilibrate at 60 mmHg for 30-60 min at 36 ± 0.5°C before the experimental protocols were initiated.
Diameter measurements. An image of the arteriole was projected onto a video monitor via a microscope-mounted charge-coupled device camera (model KP-113, Hitachi) at a final magnification of ×4. Lumen diameter of the vessel was monitored continuously by edge detection. Pressure transducers were attached at both the proximal and distal ends of the artery. Throughout all experiments, mesenteric vessels were pressurized at 60 mmHg. This pressure was monitored online from the proximal end of the vessel with the use of a pressure monitor (model PM-4, Living Systems Instrumentation; Burlington, VT). Video (diameter) and pressure were recorded simultaneously on a conventional videotape recorder (Vetter; Rebersburg, PA) and on a Pentium-based personal computer using Axoscope software (version 8, Axon Instruments; Foster City, CA) at a sampling rate of 20 Hz/channel. Final analysis was performed using Axoscope and Origin software (version 4.1, Microcal Software; Northampton, MA).
Solutions. The solution used to dissect the arteries contained (in mM) 120 NaCl, 25 NaHCO3, 4.2 KCl, 0.6 KH2PO4, 1.2 MgCl2, 11 glucose, and 1.8 CaCl2. The normal bathing (control) solution was identical to the dissecting solution. Passive diameter changes to pressure were obtained by exposing the arteriole to a Ca2+-free solution of similar composition to the dissecting solution except for the omission of CaCl2 and addition of 2 mM EGTA. The high-K+ (45 mM) solution was obtained by equiosmolar replacement of NaCl by KCl in the control solution. Test solutions were prepared by adding agents to the final concentrations into the control solution. PE and acetylcholine were prepared as 10 mM and 1 mM stock solutions, respectively, in control solutions. A stock solution of ceramide was prepared in dimethyl sulfoxide (DMSO) at concentrations of 50 mM; the final concentration of DMSO never exceeded 0.1%, which by itself produced no effect on PE-induced tone. All drugs were obtained from Sigma. Solutions were bubbled throughout with 5% CO2-12% O2-83% N2 (pH 7.4).
Equation used and statistical analysis.
Percent relaxation at 60 mmHg (%dilation) due to ceramide (Fig.
1B) was calculated using the
following equation
|
|
|
| |
RESULTS |
|---|
|
|
|---|
BK Stimulates Sphingomyelin Hydrolysis
SM is hydrolyzed by SMase to produce ceramide and phosphorylcholine. The arteries were prelabeled with [14C]choline chloride; thus a decrease in the radioactivity associated with sphingomyelin represents hydrolysis of sphingomyelin by SMase. To determine the SMase response to BK, arteries were stimulated with 10
8-10
6 M BK for
30 min (Fig. 1). At all of these concentrations of BK, [14C]SM levels decrease by ~50%, which is
significantly different from the control levels (P < 0.01, n = 3). Higher concentrations of BK did not cause
a further decrease in the levels of SM.
Concentration-Dependent Increase in Ceramide Production by BK
To confirm that BK activates SMase and to investigate the concentration response of ceramide production to BK, rat small arteries were labeled with [14C]myristic acid, and the [14C]ceramide produced was measured after stimulation of rat small arteries with different concentrations of BK (10
10-10
6 M for 30 min). The data in
Fig. 2 demonstrate a
concentration-dependent increment in ceramide as BK is increased from
10
10 M (n = 3, P < 0.05)
to 10
8 M (n = 3, P < 0.01). At 10
8 M BK, the production of
[14C]ceramide reached a level that is threefold higher
than control levels. The production of ceramide then reached a plateau
and remained at that level as the concentration of BK was increased to
10
6 M.
|
Time-Dependent Increase of Ceramide Production Induced by BK
To further determine whether BK increases SMase activity, ceramide production was measured at different times after treatment. Small arteries labeled with [14C]myristic acid were then treated with 10
8 M BK for various times. Figure
3 shows that ceramide production increased gradually with time, reaching a threefold increase at 30 min
(n = 3, P < 0.01). No further increase
was observed if the treatment was continued past 30 min. The exogenous
standard ceramide and [32P]ceramide phosphate produced by
exogenous SMase confirmed that the [32P]ceramide
phosphate induced by BK was coming from the SM pool.
|
Exogenous SMase Induces Ceramide Production
Exogenous SMase is generally used as a tool to study ceramide signal transduction and is often used as a positive control to demonstrate the hydrolysis of SM. Exogenous S. aureus SMase (0.1 U/ml) catalyses the hydrolysis of endogenous SM to form ceramide. The effect of exogenous SMase or BK on ceramide production is shown in Fig. 4. Either exogenous SMase or BK (10
8 M) catalyzed the hydrolysis of endogenous SM to form
ceramide. The [14C]ceramide production induced by
exogenous SMase or BK was significantly higher (more than twofold) than
the levels in the untreated controls (P < 0.01, n = 3).
|
BK-B1 Receptor Mediates Effect of BK on SMase
It is known that BK signals through two receptor subtypes, BK-B1 or BK-B2 (38, 49). To determine which receptor subtype is responsible for ceramide signal transduction, [14C]myristic acid-labeled rat small arteries were stimulated with 10
8 M BK for 30 min
±10
6 M BK-B1 receptor antagonist or
±10
6 M BK-B2 receptor antagonist. Figure
5 demonstrates that BK increased ceramide
levels and the presence of the BK-B2 receptor antagonist did not block the increase in ceramide levels induced by BK. In contrast, in Fig. 6, the
BK-B1 receptor antagonist completely inhibited the effect
of BK on ceramide production, indicating that the BK-B1
receptor subtype mediated the effect of BK on ceramide production in
the rat small artery.
|
|
Ceramide Effects on Vasomotor Tone
Functional experiments were performed to test the hypothesis that ceramide can influence vasomotor tone in rat mesenteric arteries of similar caliber to those used in biochemical experiments. Figure 7A illustrates a sample experiment where we tested the effects of ceramide on the lumen diameter of a preconstricted mesenteric artery pressurized to 60 mmHg. In the absence of an agonist, lumen diameter was 412 µm. These small arteries exhibited very little (<10% on average) myogenic active tone (in the absence of an agonist), which can be measured by subtracting the lumen diameter versus pressure relationship obtained in normal medium from the one registered in Ca2+-free medium (passive diameter). As shown, application of 1 µM PE, a
1-adrenergic receptor agonist, constricted the artery to a diameter of ~170 µm. Application of 50 µM ceramide in the
continued presence of PE slowly dilated the vessel, which eventually
reached a diameter ~270 µm after 62 min. Exposure of the
preparation to a bolus of ACh (1 mM) led to a rapid transient
vasorelaxation of which maximum level approached that measured in
control and Ca2+-free conditions, suggesting that the
endothelium was still functional in the presence of ceramide.
Figure 7B shows mean data from two separate series of
experiments. The graph plots the time course of changes in lumen
diameter expressed as a percentage of dilation relative to the passive
diameter (100% level) estimated in Ca2+-free EGTA medium
and maximum constriction induced by 1 µM PE (0% level). Similar to
Fig. 7A, 50 µM ceramide induced an ~35% dilation, which
took ~10 min to reach a steady state (n = 6). The
relaxation mediated by ceramide was not due to a desensitization of the
1-adrenergic receptor because the magnitude of the
PE-induced constriction remained stable for >60 min as determined in
parallel time control experiments carried out in the absence of
ceramide (n = 3, open circles).
|
We also examined the possible effects of 50 µM ceramide on
high-K+-induced constriction. As shown in Fig.
7C, increasing the concentration of K+ in the
bathing medium from 5.4 to 45 mM, 15-min exposure, reduced lumen
diameter by 57% on average. A 60-min exposure to ceramide produced no
effect on the K+-induced constriction (n = 4). Our data indicate that while ceramide had no influence on the
KCl-induced constriction, this compound partially dilated vessels,
which were preconstricted with the
1-adrenoceptor
agonist PE. These results suggest that BK-induced increased ceramide
production also influence vascular tone in resistance arteries.
| |
DISCUSSION |
|---|
|
|
|---|
Many physiological functions have been ascribed to BK, including the promotion of contraction and relaxation of vascular and nonvascular smooth muscles, renal hemodynamics, cell proliferation, inflammation, edema, and pain (9, 10, 22, 28). BK has been shown to induce relaxation of many types of arteries, for example, in coronary arteries (2, 14, 30, 32, 33), pancreaticoduodenal artery (28), and rat mesenteric arteries (3, 5, 37). Contraction has also been observed, for example, in rat tail arteries (45) and in human umbilical and rabbit jugular veins (19, 30); this contraction is sometimes transient and followed and/or preceded by relaxation (30, 32, 33).
Few reports (18, 19, 21) have investigated the effect of
BK on ceramide signaling. In human fibroblasts, BK activated sphingolipid metabolism and resulted in a rapid rise in ceramide. We
also recently reported (18) that BK acts in part by
modifying sphingolipid signal transduction. In contrast to the results
obtained with human fibroblasts, BK inhibited the production of
ceramide in RCCD cells. We speculated that BK could possibly be
involved in counteracting the effects of agents that cause the
generation of ceramide and thus have a regulating role in
vasoconstriction and vasodilatation. The present study indicates that
BK stimulates the rapid hydrolysis of sphingomyelin in rat mesenteric
small arteries. The amount of 14C-labeled sphingomyelin
obtained from arteries prelabeled with [methyl-14C]choline chloride decreases rapidly
after treatment with BK. The effect is significant within 5 min of
treatment and is maximal at 30 min. As expected, the decrease in
sphingomyelin is accompanied quite closely by an increase in ceramide.
The generation of ceramide, as measured by the generation of
14C-labeled ceramide produced after stimulation of
[14C]myristic acid-labeled cells with BK, is
concentration dependent with the maximal amount being produced in
response to 10
8 M BK. These results resemble those
obtained in human fibroblasts in response to BK treatment but differ
from the effect seen in RCCD cells (18). These results can
probably be attributed to differences in cell specificity. We used
exogenous SMase as a positive control to demonstrate the generation of
ceramide. This treatment resulted in a rapid generation of ceramide.
Exogenous SMase is widely used as a tool to investigate ceramide signal transduction. It is used to mimic the effect of ceramide generating signals (18, 19). Although it is not clear how exogenous
SMase functions to generate an intracellular signal, some of the
ceramide, which is generated on the cell surface, enters into the cell. That exogenously added SMase is very effective in hydrolyzing endogenous SM has been clearly demonstrated (18, 19, 27). Our results show that 10
8 M BK generate a ceramide signal
comparable with that of 0.1 U/ml exogenous SMase.
BK receptors are generally divided into two major subtypes, BK-B1 and BK-B2 (18, 30, 32, 33). BK acts primarily by binding to the BK-B2 receptor, which is responsible for most of the following effects of BK: arterial vasodilatation, plasma extravasation, venoconstriction, activation of sensory fibers (pain), release of prostaglandins, and relaxing factors from the endothelium (19, 30, 32, 33). BK binds to the BK-B1 receptor; however, the receptor has a much higher affinity for the metabolite des-[Arg9]-BK. To determine which BK receptor subtype affects ceramide signal transduction, [14C]myristic acid-labeled small arteries were stimulated with BK in the presence of BK receptor B1 or B2 antagonists. The BK-B2 antagonist HOE-140 did not block the effect of BK on ceramide generation. In contrast, the BK-B1 antagonist Lys-Des-Arg9-Leu8-BK, which had no effect of background levels of ceramide, blocked very efficiently the generation of ceramide induced by BK. These results suggest that the BK-B1 receptor, and not the BK-B2 receptor, mediates the ceramide-generating effect of BK.
These results are in contrast to RCCD cells where we demonstrated that the BK-B2 receptor mediates the effect of BK on the inhibition of ceramide generation. In general, it is the BK-B2 receptor that is responsible for the contraction-inducing effect of BK on vessels such as the human umbilical vein (33), the rabbit jugular vein (33), and rat tail arteries (38) or for the BK-induced relaxation of pig coronary arteries (14, 32) and pancreatic arteries (28). More importantly, the relaxation that is induced by BK in rat mesenteric arteries is also mediated by the BK-B2 receptor (33, 37). It has been demonstrated that both types of BK receptors are present on rabbit superior mesenteric artery smooth muscle cells. Stimulation of the BK-B2 receptor by BK or the BK-B1 receptor by des-[Arg9]-BK results in intracellular Ca2+ signals that are transient or sustained, respectively. We have not measured Ca2+ signals; however, it is known that ceramide and other sphingolipid metabolites are implicated in generating these signals including in smooth muscle cells (19, 26, 27).
It seems that the BK-B2 receptor mediates the effect of BK
on inhibition of SMase in RCCD cells, whereas activation of the BK-B1 receptor leads to activation of SMase in rat
mesenteric small arteries. Whether this is true of the two receptor
subtypes in other cell types remains to be determined. Also
unknown at the present time are the signaling pathways involved
downstream of the BK-B1 or BK-B2 receptors and
upstream of sphingomyelinase (Fig.
8). There are presently many potential
candidates that could be implicated: the ERK1, ERK2 mitogen-activated
protein kinase pathway, the stress-activated protein
kinase/c-jun NH2-terminal kinase or p38
pathways, various protein phosphatases, phospholipase A2,
phosphatidylinositol or phosphatidylcholine phospholipase C,
phospholipase D, protein kinase C, Ca2+, or nitric oxide
(19). Also unknown at the present time is the involvement
of other sphingolipid metabolites (sphingosine, sphingosine-1-phosphate, and ceramide-1-phosphate) in this model.
|
Our functional studies in intact rat mesenteric arteries show that a
permeable form of ceramide, at a concentration estimated to be similar
to that produced by a dose of BK eliciting maximum production of this
second messenger, significantly dilated preconstricted intact rat
mesenteric small arteries studied under isobaric condition. At the
concentration of 1 µM, the
1-agonist PE is known to
produce a contraction in this preparation that is near maximal and is entirely dependent on Ca2+ influx through voltage-gated
L-type Ca2+ channels (40). In the presence of
PE, ceramide did not attenuate contractility by suppressing smooth
muscle Ca2+ channels because it had no effect on the
constriction mediated by high-K+-induced membrane
depolarization, which is abolished by dihydropyridines (40). The lack of effect of ceramide on
high-K+-mediated constriction also rules out a nonspecific
effect of this compound on the calmodulin and myosin light chain kinase pathway leading to actomyosin interaction.
Several possibilities could explain the effects of ceramide on
PE-induced tone: 1) hyperpolarization of the smooth muscle cells by either enhancement of K+ channel activity
(25) or block of Ca2+-activated
Cl
(31) or nonselective cation
(39) channels would result in reduced Ca2+
influx through voltage-gated L-type Ca2+
channels; 2) alterations in ion channel activity or the
signaling pathways controlling the release of endothelium-derived
relaxing (nitric oxide, prostaglandin I2, and
endothelial-derived hyperpolarizing factor) or constricting
(endothelin) factors; 3) modulation of the
1-adrenoceptor signaling pathway in the smooth muscle
cells leading to a reduced sensitivity of the contractile machinery to
intracellular Ca2+ levels. In contrast with our study,
ceramide has been reported (17) to constrict bovine
coronary arteries, possibly by inhibiting Ca2+-dependent
K+ channels through a redox mechanism.
Interestingly, Ca2+-dependent K+ channels channels appear to play, at most, a minor role in the response of rabbit mesenteric arterial smooth muscle cells to PE (23). Recently, Zhang et al. (43) showed that ceramide constricts bovine small coronary arteries by impairing nitric oxide-mediated vasorelaxation, which would appear to involve an increased production of superoxide anion. Our results demonstrate in rat mesenteric small arteries: 1) the presence of SMase, 2) SM hydrolysis is induced by BK, 3) SMase is activated by BK, 4) ceramide is generated in a time- and concentration-dependent manner, 5) the BK-B1 receptor subtype is implicated in mediating the effect of BK on activation of SMase, and 6) ceramide induces a vasodilatation in mesenteric arteries, suggesting that ceramide bear differential effects on vascular tone in different vascular beds.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Marie-Andrée Lupien for excellent technical and analytical assistance in the functional studies. The BK-B1 and BK-B2 receptor antagonists were a generous gift from Dr. Domenico Regoli, Department of Pharmacology, Faculty of Medicine, University of Sherbrooke.
| |
FOOTNOTES |
|---|
* L. Kleine and G. Liu contributed equally to this work.
This study was supported by the Kidney Foundation of Canada, Canadian Institutes of Health Research Grant MT-14103 (to R. L. Hébert), by the Heart and Stroke Foundation of Québec, the Canadian Institutes of Health Research, and by the Montréal Heart Institute (to N. Leblanc). N. Leblanc holds a Fonds de la Recherche en Santé du Québec scholarship.
Address for reprint requests and other correspondence: R. L. Hébert, Dept. of Cellular and Molecular Medicine, Univ. of Ottawa, 451 Smyth Rd., Rm. 1337, Ottawa, Ontario K1H 8M5, Canada (E-mail: rlhebert{at}uottawa.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published September 27, 2001; 10.1152/ajpheart.00379.2001
Received 8 May 2001; accepted in final form 11 September 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Allan-Yorke, J,
Record M,
de Preval C,
Davrinche C,
and
Davignon JL.
Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection.
J Virol
72:
2316-2322,
1998.
2.
Auge, N,
Andrieu N,
Negresalvayre A,
Thiers JC,
Levade T,
and
Salvayre R.
The sphingomyelin-ceramide signaling pathway is involved in oxidized low-density lipoprotein-induced cell proliferation.
J Biol Chem
271:
19251-19255,
1996.
3.
Ballou, LR,
Laulederkind SJ,
Rosloniec EF,
and
Raghow R.
Ceramide signaling and the immune response.
Biochim Biophys Acta
1301:
273-287,
1996.
4.
Bligh, EG,
and
Dyer WJ.
A rapid method of total lipid extraction and purification.
Can J Biochem Physiol
37:
911-917,
1959.
5.
Brindley, DN,
Abousalham A,
Kikuchi Y,
Wang CN,
and
Waggoner DW.
"Cross talk" between the bioactive glycerolipids and sphingolipids in signal transduction.
Biochem Cell Biol
74:
469-476,
1996.
6.
Chen, J,
Nikolova-Karakashian M,
Merrill AH, Jr,
and
Morgan ET.
Regulation of cytochrome P450 2C11 (CYP2C11) gene expression by interleukin-1, sphingomyelin hydrolysis, and ceramides in rat hepatocytes.
J Biol Chem
270:
25233-25238,
1995.
7.
Coroneos, E,
Martinez M,
McKenna S,
and
Kester M.
Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines: implications for cellular proliferation and differentiation.
J Biol Chem
270:
23305-23309,
1995.
8.
Dobrowsky, RT,
Werner MH,
Castellino AM,
Chao MV,
and
Hannun YA.
Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor.
Science
265:
1596-1599,
1994.
9.
El-Dahr, SS,
Dipp S,
and
Baricos WH.
Bradykinin stimulates the ERK, Elk-1, Fos/AP-1 pathway in mesangial cells.
Am J Physiol Renal Physiol
275:
F343-F352,
1998.
10.
Field, FJ,
Chen H,
Born E,
Dixon B,
and
Mathur S.
Release of ceramide after membrane sphingomyelin hydrolysis decreases the basolateral secretion of triacylglycerol and apolipoprotein B in cultured human intestinal cells.
J Clin Invest
92:
2609-2619,
1993.
11.
Fitzgerald, V,
Blank ML,
and
Snyder F.
Molecular species of sphingomyelin in sphingomyelinase-sensitive and sphingomyelinase-resistant pools of HL-60 cells.
Lipids
130:
805-809,
1995.
12.
Galve-Roperh, I,
Sanchez C,
Segui B,
Haro A,
Diaz-Laviada I,
and
Levade L.
Evidence for the lack of involvement of sphingomyelin hydrolysis in the tumor necrosis factor-induced secretion of nerve growth factor in primary astrocyte cultures.
J Neurochem
71:
498-505,
1998.
13.
Gerritsen, ME,
Shen CP,
and
Perry CA.
Synovial fibroblasts and the sphingomyelinase pathway: sphingomyelin turnover and ceramide generation are not signaling mechanisms for the actions of tumor necrosis factor-alpha.
Am J Pathol
152:
505-512,
1998.
14.
Gorelik, G,
Carbini LA,
and
Scicli AG.
Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery.
J Pharmacol Exp Ther
286:
403-410,
1998.
15.
Huwiler, A,
Brunner J,
Hummel R,
Vervoordeldonk M,
Stabel S,
van den Bosch H,
and
Pfeilschifter J.
Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase.
Proc Natl Acad Sci USA
93:
6959-6963,
1996.
16.
Johns, DG,
and
Webb RC.
TNF-
-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent signaling.
Am J Physiol Heart Circ Physiol
275:
H1592-H1598,
1998.
17.
Li, PL,
Zhang DX,
Zou AP,
and
Campbell WB.
Effect of ceramide on KCa channel activity and vascular tone in coronary arteries.
Hypertension
33:
1441-1446,
1999.
18.
Liu, G,
Kleine L,
Nasrallah R,
and
Hébert RL.
Bradykinin inhibits ceramide production and activates phospholipase D in rabbit RCCD cells.
Am J Physiol Renal Physiol
276:
F589-F598,
1999.
19.
Liu, G,
Kleine L,
and
Hébert RL.
Advances in the signal transduction of ceramide and related sphingolipids.
Crit Rev Clin Lab Sci
36:
511-573,
1999.
20.
Lowry, OH,
Rosebrough NJ,
Farr AL,
and
Randall RJ.
Protein measurement with the Folin phenol reagent.
J Biol Chem
193:
265-275,
1951.
21.
Meacci, E,
Vasta V,
Farnararo M,
and
Bruni P.
BK increases ceramide and sphingosine content in human fibroblasts: possible involvement of glycosphingolipids.
Biochem Biophys Res Commun
221:
1-7,
1996.
22.
Merrill, AH,
Lingrell S,
Wang E,
Nikolova-Karakashian M,
Vales TR,
and
Vance DE.
Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion.
J Biol Chem
270:
13834-13841,
1995.
23.
Mistry, DK,
and
Garland CJ.
The influence of phenylephrine on outward potassium currents in single smooth muscle cells from the rabbit mesenteric artery.
Gen Pharmacol
33:
389-399,
1999.
24.
Murohara, T,
Kugiyama K,
Ohgushi M,
Sugiyama S,
Ohta Y,
and
Yasu H.
Effects of sphingomyelinase and sphingosine on arterial vasomotor regulation.
J Lipid Res
37:
1601-1608,
1996.
25.
Nelson, MT,
Patlak JB,
Worley JF,
and
Standen NB.
Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone.
Am J Physiol Cell Physiol
259:
C3-C18,
1990.
26.
Ohanian, J,
Ohanian V,
Shaw L,
Bruce C,
and
Heagerty AM.
Involvement of tyrosine phosphorylation in endothelin-1-induced calcium-sensitization in rat small mesenteric arteries.
Br J Pharmacol
120:
653-661,
1997.
27.
Ohanian, J,
Liu G,
Ohanian V,
and
Heagerty AM.
Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function.
Acta Physiol Scand
164:
533-548,
1998.
28.
Pawlik, WW,
Sendur R,
Biernat J,
and
Koziol R.
Nitric oxide as mediator of bradykinin-induced pancreatic circulatory and metabolic responses.
J Physiol Pharmacol
48:
751-760,
1997.
29.
Peña, LA,
Fuks Z,
and
Kolesnick R.
Stress-induced apoptosis and the sphingomyelin pathway.
Biochem Pharmacol
53:
615-621,
1997.
30.
Regoli, D,
Marceau F,
and
Lavigne J.
Induction of B1 receptors for kinins in the rabbit by a bacterial lipopolysaccharide.
Eur J Pharmacol
71:
105-115,
1981.
31.
Remillard, CV,
Lupien MA,
Crepeau V,
and
Leblanc N.
Role of Ca2+- and swelling-activated Cl
channels in
1-adrenoceptor-mediated tone in pressurized rabbit mesenteric arterioles.
Cardiovasc Res
46:
557-568,
2000.
32.
Rizzi, A,
Calo G,
Amadesi S,
and
Regoli D.
Kinin B1 and B2 receptors in pig vessels: characterization of two monoreceptor systems.
Arch Pharm (Weinheim)
356:
662-670,
1997.
33.
Rizzi, A,
Rizzi C,
Amadesi S,
Calo G,
Varani K,
Inamura N,
and
Regoli D.
Pharmacological characterization of the first non-peptide BK-B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors.
Arch Pharm (Weinheim)
360:
361-367,
1999.
34.
Robinson, M,
and
Cobb M.
Mitogen-activated protein kinase pathways.
Curr Opin Cell Biol
9:
180-186,
1997.
35.
Sbrissa, D,
Yamada H,
Hajra A,
and
Bitar KN.
Bombesin-stimulated ceramide production and MAP kinase activation in rabbit rectosigmoid smooth muscle cells.
Am J Physiol Gastrointest Liver Physiol
272:
G1615-G1625,
1997.
36.
Schissel, SL,
Keesler GA,
Schuchman EH,
Williams KJ,
and
Tabas I.
The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene.
J Biol Chem
273:
18250-18259,
1998.
37.
Shimuta, SI,
Barbosa AM,
Borges AC,
and
Paiva TB.
Pharmacological characterization of RMP-7, a novel bradykinin agonist in smooth muscle.
Immunopharmacology
45:
63-67,
1999.
38.
Wang, Z,
Wu L,
and
Wang R.
Kinin B2 receptor-mediated contraction of tail arteries from normal or streptozotocin-induced diabetic rats.
Br J Pharmacol
125:
143-151,
1998.
39.
Welsh, DG,
Nelson MT,
Eckman DM,
and
Brayden JE.
Swelling-activated cation channels mediate depolarization of rat cerebrovascular smooth muscle by hyposmolarity and intravascular pressure.
J Physiol (Lond)
527:
139-148,
2000.
40.
Wesselman, JPM,
Vanbavel E,
Pfaffendorf M,
and
Spaan JAE
Voltage-operated calcium channels are essential for the myogenic responsiveness of cannulated rat mesenteric small arteries.
J Vasc Res
33:
32-41,
1996.
41.
Yanaga, F,
and
Watson SP.
Ceramide does not mediate the effect of tumour necrosis factor alpha on superoxide generation in human neutrophils.
Biochem J
298:
733-738,
1994.
42.
Yao, B,
Zhang Y,
Delikat S,
Mathias S,
Basu M,
and
Kolesniek R.
Ceramide-activated protein kinase is a Raf kinase.
Nature
378:
307-310,
1995.
43.
Zhang, DX,
Zou AP,
and
Li PL.
Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries.
Circ Res
88:
824-831,
2001.
This article has been cited by other articles:
![]() |
P. D. Constable, G. W. Smith, G. E. Rottinghaus, M. E. Tumbleson, and W. M. Haschek Fumonisin-induced blockade of ceramide synthase in sphingolipid biosynthetic pathway alters aortic input impedance spectrum of pigs Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2034 - H2044. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |